Cytochrome bd-type oxidase (cytochrome bd oxidase)

Cytochrome bd-type oxidase is a prokaryotic terminal respiratory oxidase functioning in the inner membrane of many bacteria and some archaea. It catalyzes the final step of the aerobic electron transport chain: the reduction of molecular oxygen to water using electrons derived from quinol. Uniquely, cytochrome bd-type oxidase contains three heme cofactors (two b-type and one d-type heme) arranged in a triangular configuration and lacks copper centers present in classical heme-copper oxidases. The canonical enzyme is composed of at least two subunits, CydA and CydB, often with one or two additional small subunits (CydX, CydH), depending on the species[1][2][3][5][6]. This oxidase is distinct from other respiratory oxidases in its structure, resistance to cyanide, absence of proton pumping, and its ability to maintain electron transport during hypoxic stress, nitrate-rich conditions, or exposure to host antimicrobial factors[7][8]. It supports the survival and pathogenesis of many bacterial species, making it a validated therapeutic target for novel antibiotics, particularly against multidrug-resistant pathogens. Several experimental inhibitors exist, with selective targeting made possible by its lack of homology to mammalian oxidases[5][6]. Caveats and limitations: - The enzyme is not present in mammals. - No currently approved drugs target it clinically; all inhibitors mentioned are investigational or research-only. - Biomarkers for clinical use not established.

Other names

cytochrome bd oxidasecytochrome bdcytochrome bd ubiquinol oxidasecytochrome bd terminal oxidase

Drugs targeting cytochrome bd-type oxidase inhibit electron transport and respiratory oxygen reduction in prokaryotes, leading to impaired energy generation and potentially reduced viability or virulence of pathogenic bacteria[5][6]. Inhibition increases susceptibility to oxidative stress and host immune responses.